Drug Sales Trends for MIRTAZAPINE

Payment Methods and Pharmacy Types for MIRTAZAPINE (2017)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$3,622,108
INSIDE ANOTHER STORE	$22,377,674

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	196,775
INSIDE ANOTHER STORE	613,941

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$59,315,033
MEDICARE	$102,345,731

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for MIRTAZAPINE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
MIRTAZAPINE			2022
MIRTAZAPINE			2021
MIRTAZAPINE			2020
MIRTAZAPINE			2019
MIRTAZAPINE			2018
MIRTAZAPINE			2017

Mirtazapine Market Analysis, Sales Forecast, Patent Status, and Generic Competition

Last updated: September 7, 2026

Mirtazapine is a mature, fully generic antidepressant with limited brand revenue and low patent risk. The market is driven by prescription volume, low-cost generic supply, and continued use in major depressive disorder where insomnia, poor appetite, or weight loss are clinical considerations. Global mirtazapine sales are likely concentrated in low-price generic channels, with limited opportunity for premium pricing unless a company develops a differentiated formulation or combination product.

A reasonable base-case estimate places global mirtazapine market value at approximately $350 million to $550 million in 2025, measured at manufacturer and distributor revenue rather than retail sales. The market is likely to decline modestly in nominal value through 2030 as price competition offsets stable or slightly increasing prescription volume.

What is mirtazapine and how is it used?

Mirtazapine is a noradrenergic and specific serotonergic antidepressant approved in the United States for major depressive disorder in adults. The original brand, Remeron, was developed by Organon and later commercialized by Schering-Plough and Merck. Remeron SolTab is the orally disintegrating tablet version. Both products have faced generic competition for many years.

Mirtazapine is available in:

Dosage form	Common strengths	Commercial status
Immediate-release tablet	15 mg, 30 mg, 45 mg	Generic
Orally disintegrating tablet	15 mg, 30 mg, 45 mg	Generic
Brand tablet, Remeron	15 mg, 30 mg, 45 mg	Legacy or limited availability
Brand orally disintegrating tablet, Remeron SolTab	15 mg, 30 mg, 45 mg	Legacy or limited availability

The usual starting dose is 15 mg once daily, generally administered at bedtime. The FDA-approved labeling identifies somnolence, increased appetite, weight gain, dizziness, and dry mouth among common adverse reactions. The label also carries antidepressant class warnings concerning suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients. Mirtazapine is not approved by the FDA for pediatric major depressive disorder.[1]

How large is the mirtazapine market?

The market is substantial in prescription volume but small in branded pharmaceutical value. Mirtazapine competes in the mature antidepressant segment against generic sertraline, escitalopram, fluoxetine, bupropion, venlafaxine, duloxetine, trazodone, and paroxetine.

Public company filings generally do not report mirtazapine revenue separately because the product is generic and sold through diversified portfolios. Market estimates therefore depend on prescription counts, dosage mix, geographic pricing, and channel assumptions.

Estimated 2025 global market

Market measure	2025 estimate
Global prescription volume	90 million to 130 million monthly treatment equivalents
Global manufacturer-level value	$350 million to $550 million
Global retail value	$700 million to $1.2 billion
U.S. manufacturer-level value	$80 million to $150 million
U.S. retail and pharmacy-channel value	$180 million to $350 million
Branded Remeron contribution	De minimis relative to generic sales

The wide value range reflects differences in generic pricing. A 30-day supply of generic mirtazapine may cost only a few dollars in high-volume markets, while private-pay prices can be materially higher in some countries. Orally disintegrating tablets also carry a price premium in certain channels, although generic competition has narrowed that premium.

What are the mirtazapine sales projections through 2030?

The base case assumes stable underlying demand, gradual unit growth in aging populations, continued generic price erosion, and no major branded reformulation. Under those assumptions, value declines even if prescription volume is stable.

Global mirtazapine market forecast

Year	Bear case	Base case	Bull case
2025	$325 million	$450 million	$575 million
2026	$310 million	$440 million	$580 million
2027	$295 million	$430 million	$590 million
2028	$280 million	$420 million	$600 million
2029	$265 million	$410 million	$605 million
2030	$250 million	$400 million	$610 million
2025-2030 CAGR	-5.1%	-2.3%	1.2%

The base case projects a market decline of about 2% annually. Volume is expected to remain comparatively resilient because mirtazapine is inexpensive, established in clinical practice, and used in patients for whom sedation or appetite stimulation can be clinically useful. Price erosion is the primary constraint on revenue.

The bull case requires one or more of the following developments:

• Increased prescribing in older adults with depression, insomnia, or appetite loss.
• Greater use of orally disintegrating tablets in patients with swallowing difficulty.
• Supply disruptions affecting competing antidepressants.
• Premium pricing for a differentiated delivery system.
• Expansion in emerging markets with rising diagnosis and treatment rates.

The bear case reflects accelerated generic price compression, substitution by low-cost SSRIs, declining use for off-label insomnia, and fewer suppliers maintaining commercially active mirtazapine portfolios.

When does mirtazapine lose exclusivity?

Mirtazapine lost meaningful U.S. market exclusivity years ago. The original Remeron product was approved in 1996, and generic products entered the U.S. market after expiration of the relevant patent and regulatory exclusivity barriers.[2]

Milestone	Approximate timing
Original Remeron FDA approval	1996
Remeron SolTab approval	2001
Generic tablet competition	Early 2000s
Generic orally disintegrating tablet competition	Mid-2000s onward
Current U.S. patent barrier	No material blocking patent expected
Current commercial status	Mature generic market

Mirtazapine is therefore not an asset with a conventional loss-of-exclusivity event ahead. The commercial question is supply economics, not the timing of generic entry.

What patents protect mirtazapine?

The core composition-of-matter protection for mirtazapine has expired. Current patent risk is limited to narrow formulation, process, packaging, or device claims rather than the active ingredient itself.

Potentially relevant patent categories include:

1. Drug substance manufacturing processes.
2. Crystal form or polymorph claims.
3. Orally disintegrating tablet compositions.
4. Taste-masking technologies.
5. Modified-release delivery systems.
6. Combination products.
7. Method-of-use claims for specific populations or symptoms.

These rights generally do not prevent standard generic tablets from entering the market. A process patent may affect manufacturing economics without blocking a competitor that uses a non-infringing process. A formulation patent may create a narrower commercial position for an orally disintegrating or modified-release product, but it does not restore exclusivity for conventional tablets.

What is the Orange Book status of mirtazapine?

The FDA Orange Book historically listed Remeron and Remeron SolTab products with patent information associated with the branded products. Current generic competition means that ordinary mirtazapine tablets and orally disintegrating tablets are established abbreviated new drug application products rather than protected branded products.[3]

The key commercial conclusions are:

• No active composition-of-matter exclusivity protects standard mirtazapine.
• Paragraph IV litigation is unlikely to affect the ordinary generic market.
• Any remaining listed patent issue would likely concern a specific formulation or product presentation.
• Generic applicants can generally compete on standard tablet strengths without waiting for a future loss-of-exclusivity date.

Are there Paragraph IV challenges to mirtazapine?

Paragraph IV challenges were commercially relevant when generic companies first sought approval for Remeron and Remeron SolTab products. They are no longer a central market event because generic mirtazapine has been available for many years.

Current commercial risk does not depend on a new Paragraph IV filing. It depends on:

• The number of active manufacturers.
• API availability.
• FDA manufacturing compliance.
• Contracting with wholesalers and pharmacy benefit managers.
• Channel-specific price competition.
• Supply continuity for 15 mg, 30 mg, and 45 mg strengths.

For an investor or originator, a new Paragraph IV campaign would have limited strategic value unless linked to a new formulation with meaningful differentiation.

What companies compete in the mirtazapine market?

The market has historically included large generic manufacturers and specialty suppliers such as Teva, Sandoz, Mylan, Zydus, Dr. Reddy's Laboratories, Aurobindo, Torrent, Sun Pharma, and other regional manufacturers. Corporate ownership and product availability have changed over time, and not every company continuously markets every strength or dosage form.

Competition is fragmented. No single manufacturer is likely to control the global market across all territories. Local registration, procurement contracts, and wholesaler relationships are more important than brand recognition.

Competitive structure by product type

Product type	Competitive intensity	Margin outlook
15 mg standard tablet	Very high	Low
30 mg standard tablet	Very high	Low
45 mg standard tablet	High	Low to moderate
Orally disintegrating tablet	Moderate to high	Moderate where differentiated
Modified-release product	Low	Potentially higher, subject to clinical and patent support
Combination product	Low	Higher potential but greater regulatory risk

A company entering standard tablets would face a commodity market. A company entering an orally disintegrating tablet could obtain better pricing only if the product improves adherence, taste, administration, or supply reliability.

What formulations are protected by mirtazapine patents?

The most commercially relevant formulation opportunity is the orally disintegrating tablet. Remeron SolTab was designed for patients who have difficulty swallowing conventional tablets. Generic orally disintegrating versions have reduced the opportunity for a premium branded product.

Potential differentiation remains in:

• Faster disintegration.
• Improved taste masking.
• Lower friability.
• Better stability under humidity.
• Unit-dose packaging.
• Pediatric or geriatric administration.
• Lower-cost manufacturing.
• Combination with digital adherence or specialty pharmacy services.

A new formulation would need to demonstrate a commercial advantage large enough to offset development, manufacturing, and regulatory costs. A basic reformulation without a meaningful clinical or handling benefit would face rapid generic substitution.

What is the FDA regulatory status of mirtazapine?

Mirtazapine is an FDA-approved prescription drug for major depressive disorder in adults. Generic tablets and orally disintegrating tablets are approved through the abbreviated new drug application pathway, which generally requires demonstration of pharmaceutical equivalence and bioequivalence rather than a new efficacy trial.[1][4]

Key regulatory characteristics include:

• FDA-approved active ingredient: mirtazapine.
• Primary approved indication: major depressive disorder in adults.
• Generic pathway: ANDA.
• Pediatric approval for depression: none.
• Controlled-substance status: not scheduled under the federal Controlled Substances Act.
• Regulatory complexity: low for standard immediate-release products; higher for novel delivery systems or combination products.

Off-label use is common in clinical practice, particularly for insomnia, appetite loss, and anxiety-related symptoms, but those uses do not expand the FDA-approved label or create automatic market exclusivity.

What generic entry risks exist for mirtazapine?

Generic entry risk is already realized rather than prospective. The principal risks for a mirtazapine manufacturer are margin compression and portfolio rationalization.

Manufacturer risks

• Additional suppliers can reduce prices quickly.
• Low-volume strengths may be discontinued.
• API sourcing disruptions can affect multiple manufacturers.
• Wholesalers may shift purchases toward the lowest-cost supplier.
• Pharmacy benefit managers may prefer a narrow group of manufacturers.
• FDA warning letters or manufacturing observations can remove capacity.
• Retail demand can shift between tablet and orally disintegrating formats.

Originator risks

For the original brand owner, residual revenue exposure is limited. The brand has no realistic path to regain mass-market share without a new formulation, a new indication supported by clinical evidence, or a licensing arrangement with a differentiated delivery technology.

How does mirtazapine compare with other antidepressants?

Mirtazapine has a different commercial and clinical profile from the leading generic SSRIs.

Drug	Market position	Key differentiator	Generic price pressure
Mirtazapine	Mature generic	Sedation and appetite effects	Very high
Sertraline	High-volume generic	Broad first-line use	Very high
Escitalopram	High-volume generic	Tolerability and efficacy	Very high
Fluoxetine	Mature generic	Long half-life and low cost	Very high
Bupropion	High-volume generic	Lower sexual side-effect burden for some patients	Very high
Trazodone	Generic	Sedating, often used off label for insomnia	Very high
Duloxetine	Generic	Depression plus neuropathic pain indications	High
Venlafaxine	Generic	Broad antidepressant use	High

Mirtazapine's competitive advantage is not patent-based. It is clinical positioning. Prescribers may select it when insomnia, weight loss, nausea, or poor appetite are relevant. Its principal commercial disadvantage is sedation and weight gain, which can lead to discontinuation or substitution.

What licensing deals affect mirtazapine?

No major current licensing transaction is required to commercialize standard mirtazapine tablets in the United States. The product is available through generic licensing, contract manufacturing, and distribution arrangements rather than through a high-value originator partnership.

A licensing opportunity could arise around:

• Long-acting injectable mirtazapine.
• Modified-release delivery.
• Fixed-dose combinations.
• Geriatric or dysphagia-focused formulations.
• Digital adherence programs tied to specialty distribution.
• Geographic rights in markets where generic access remains limited.

The economic value of such a deal would depend on differentiated clinical utility. A license covering ordinary immediate-release mirtazapine would have limited value because multiple equivalent products already exist.

What is the revenue exposure for pharmaceutical companies?

Revenue exposure is asymmetric.

Stakeholder	Revenue exposure
Original brand owner	Low and declining
Large generic manufacturer	Low per product, but meaningful across volume
API supplier	Moderate if supplying multiple finished-dose manufacturers
Specialty formulation developer	Potentially high if a premium product succeeds
Wholesaler and pharmacy	Low margin, high transaction volume
Payer	Low absolute spend relative to newer branded therapies

Mirtazapine is unlikely to be a material revenue driver for a diversified pharmaceutical company. It can still be commercially useful as part of a generic CNS portfolio, especially where the manufacturer has low-cost API access and established pharmacy distribution.

What is the likely generic launch scenario?

A new entrant would likely face the following launch conditions:

1. Standard tablets would enter a crowded market with low pricing.
2. The 15 mg strength would likely have the greatest volume but the most competition.
3. The 45 mg strength could have fewer suppliers and somewhat better economics.
4. Orally disintegrating tablets may support higher gross margins than standard tablets.
5. Hospital and institutional contracts could provide volume but impose aggressive price concessions.
6. Regulatory compliance and supply reliability would matter more than promotional spending.

The strongest entry strategy would combine low-cost manufacturing with reliable supply and a formulation advantage. A conventional tablet-only launch would likely produce modest revenue and low operating margins.

How strong is the mirtazapine patent estate?

The patent estate is weak for the active ingredient and standard tablets, but potentially moderate for narrow delivery technologies.

Patent category	Strength today	Ability to block generic tablets
Composition of matter	Expired	None
Standard tablet formulation	Weak or expired	None
Orally disintegrating tablet	Product-specific	Limited
Manufacturing process	Potentially active in some jurisdictions	Usually indirect
Modified release	Potentially stronger if valid	Product-specific
Combination product	Potentially moderate	Depends on claim scope
Method of use	Limited commercial value	Usually does not block all sales

Patent enforcement would be difficult unless a competitor copied a protected formulation or manufacturing process. Patent litigation is not a central risk for ordinary generic mirtazapine.

What is the geographic market opportunity?

The largest commercial markets are the United States, Western Europe, Japan, Canada, Australia, and selected Central and Eastern European markets. Emerging markets may generate higher unit growth but lower prices.

Geographic outlook

Region	Volume outlook	Price outlook	Commercial assessment
United States	Stable	Low	Large, mature generic market
Western Europe	Stable to modest growth	Low to moderate	Tender and reimbursement driven
Japan	Stable	Moderate	Local regulatory and distribution requirements
China	Growth potential	Low	Competitive domestic supply
India	High volume	Very low	Strong generic competition
Latin America	Modest growth	Variable	Country-specific access and pricing
Middle East and Africa	Modest growth	Variable	Procurement and supply reliability matter

The United States and Europe will likely remain the largest value markets, while India, China, and other emerging markets may account for a greater share of unit growth.

Key Takeaways

• Mirtazapine is a mature, fully generic antidepressant with no meaningful upcoming loss-of-exclusivity event.
• Estimated global 2025 manufacturer-level market value is approximately $350 million to $550 million.
• A base-case forecast projects roughly $400 million in global value by 2030.
• Prescription volume should remain comparatively stable, but generic price erosion will pressure revenue.
• Standard tablets are commodity products with low margins.
• Orally disintegrating, modified-release, and combination formulations offer the strongest remaining commercial opportunities.
• Paragraph IV litigation and biosimilar risk are not material to mirtazapine. Biosimilars are irrelevant because mirtazapine is a small-molecule drug.
• The principal risks are supplier concentration, API disruptions, manufacturing compliance, and reimbursement-driven price competition.
• The strongest commercial position belongs to manufacturers with low-cost production, broad geographic registrations, and reliable supply.

FAQs About Mirtazapine Market Size and Commercial Outlook

Is mirtazapine still profitable for generic manufacturers?

Yes, but profitability depends on production cost, manufacturing scale, and supply reliability. Standard tablets generate low margins, while less crowded strengths and orally disintegrating products may provide better economics.

Does mirtazapine have biosimilar competition?

No. Mirtazapine is a chemically synthesized small-molecule drug, so competition occurs through generic drugs approved under the ANDA pathway rather than biosimilars.

Can a new company obtain exclusivity for a mirtazapine product?

Potentially, but not for the old active ingredient alone. A company would need a qualifying new formulation, combination product, clinical indication, or other patentable innovation.

Is Remeron still commercially important?

Remeron has limited commercial importance compared with generic mirtazapine. The branded product's historical value has largely transferred to generic manufacturers and distributors.

What mirtazapine product has the best market opportunity?

A differentiated orally disintegrating or modified-release product has the strongest potential. A standard immediate-release tablet would enter a mature, highly competitive market with limited pricing power.

References

1. U.S. Food and Drug Administration. (2024). Mirtazapine tablets: Prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (1996). Remeron (mirtazapine) approval history. Drugs@FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.